Dehydrocorybulbine is primarily recognized for its analgesic and anti-inflammatory properties. It has been studied for use in managing chronic pain, particularly neuropathic and inflammatory pain, due to its ability to modulate dopamine receptors and influence pain signaling pathways. Unlike traditional opioids, it may offer pain relief with a lower risk of dependence, making it a candidate for development in non-opioid pain therapies. It also shows potential in reducing symptoms associated with liver fibrosis and certain autoimmune conditions due to its anti-inflammatory effects. Research is ongoing to explore its efficacy and safety in clinical settings.